Obesity and kidney disease: Differential effects of obesity on adipose tissue and kidney inflammation and fibrosis

Current Opinion in Nephrology and Hypertension

Volumn 24, Issue 1, 2015, Pages 28-36

  Declèves, Anne Emilie ^a,b   Sharma, Kumar ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AMPK; HIF 1 ; NADPH oxidase; Nutrient stress; TGF

Indexed keywords

FATTY ACID DERIVATIVE; G PROTEIN COUPLED RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; CYTOKINE; HIF1A PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSFORMING GROWTH FACTOR BETA;

ADIPOSE TISSUE; CALORIC INTAKE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; LIPID STORAGE; METABOLIC SYNDROME X; NEPHRITIS; NONHUMAN; OBESITY; REVIEW; SIGNAL TRANSDUCTION; COMPLICATION; FIBROSIS; INFLAMMATION; KIDNEY; METABOLISM; PATHOLOGY;

ADIPOSE TISSUE; AMP-ACTIVATED PROTEIN KINASES; CYTOKINES; FIBROSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFLAMMATION; INSULIN RESISTANCE; KIDNEY; NADPH OXIDASE; NEPHRITIS; OBESITY; RECEPTORS, G-PROTEIN-COUPLED; TRANSFORMING GROWTH FACTOR BETA;

EID: 84918503918     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000087     Document Type: Review

References (126)

1. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012; 148:852-871.
2. Bruce KD, Hanson MA. The developmental origins, mechanisms, and implications of metabolic syndrome. J Nutr 2010; 140:648-652.
3. Collins AJ, Foley RN, Herzog C, et al. US Renal Data System 2010 annual data report. Am J Kidney Dis 2011; 57 (1 Suppl. 1):A8; e1-e526.
4. Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol 2014; 220:T47-T59.
5. Sikaris KA. The clinical biochemistry of obesity-more than skin deep. Heart Lung Circ 2007; 16 (Suppl. 3):S45-S50.
6. Marcussen N. Atubular glomeruli and the structural basis for chronic renal failure. Lab Invest 1992; 66:265-284.
7. Taft JL, Nolan CJ, Yeung SP, et al. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994; 43:1046-1051.
8. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999; 56:1627-1637.
9. Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000; 278:F817-F822.
10. Rosen ED, Spie gelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444:847-853.
11. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003; 27 (Suppl. 3):S53-S55.
12. Bluher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 2009; 117:241-250.
13. Makki K,Froguel P,Wolowczuk I., Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines, ISRN Inflamm, 2013;2013: 139239.
14. Liao MT, Sung CC, Hung KC, et al. Insulin resistance in patients with chronic kidney disease. J Biomed Biotechnol 2012; 2012:691369.
15. Chen J, Muntner P, Hamm LL, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003; 14:469-477.
16. Parvanova AI, Trevisan R, Iliev IP, et al. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes 2006; 55:1456-1462.
17. Abrass CK, Raugi GJ,Gabourel LS, Lovett DH. Insulin and insulin-like growth factor I binding to cultured rat glomerular mesangial cells. Endocrinology 1988; 123:2432-2439.
18. Kreisberg JI. Insulin requirement for contraction of cultured rat glome rular mesangial cells in response to angiotensin II: possible role for insulin in modulating glomerular hemodynamics. Proc Natl Acad Sci USA 1982; 79:4190-4192.
19. Cusumano AM, Bodkin NL, Hansen BC, et al. Glomerular hypertrophy is associated with hyperinsulinemia and precedes overt diabetes in aging rhesus monkeys. Am J Kidney Dis 2002; 40:1075-1085.
20. Manrique C, Lastra G, Sowers JR. New insights into insulin action and resistance in the vasculature. Ann N Y Acad Sci 2014; 1311:138-150.
21. Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 2005; 87:99-109.
22. Welsh GI, Hale LJ, Eremina V, et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 2010; 12:329-340.
23. Amann K, Benz K. Structural renal changes in obesity and diabetes. Semin Nephrol 2013; 33:23-33.
24. Thethi T, Kamiyama M, Kobori H. The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep 2012; 14:160-169.
25. Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000; 77:S93-S98.
26. Praga M, Hernandez E, Morales E, et al. Clinical features and long-term outcome of obesity-as sociated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001; 16:1790-1798.
27. Gupte M, Boustany-Kari CM, Bharadwaj K, et al. ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol 2008; 295:R781-R788.
28. Lu H, Boustany-Kari CM, Daugherty A, Cassis LA. Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab 2007; 292:E1280-E1287.
29. Ogihara T, Asano T, Ando K, et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002; 40:872-879.
30. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009; 302:128-139.
31. Prasannarong M, Santos FR, Henriksen EJ. ANG-(1-7) reduces ANG II-induced insulin resistance by enhancing Akt phosphorylation via a Mas receptor-dependent mec hanism in rat skeletal muscle. Biochem Biophys Res Commun 2012; 426:369-373.
32. El-Atat FA, Stas SN, McFarlane SI, Sowers JR. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol 2004; 15:2816-2827.
33. Kim JA, Jang HJ, Martinez-Lemus LA, Sowers JR. Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitri c oxide synthase and vasodilation. Am J Physiol Endocrinol Metab 2012; 302:E201-E208.
34. Lastra G,Habibi J,Whaley-Connell AT,et al. Direct renin inhibition improves systemic insulin resistan ce and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression, Endocrinology, 2009, 150, 2561-2568.
35. Lastra-Lastra G, Sowers JR, Restrepo-Erazo K, et al. Role of aldosterone and angiotensin II in insulin resistance: an update. Clin Endocrinol (Oxf) 2009; 71:1-6.
36. Blendea MC, Jacobs D, Stump CS, et al. Abrogation of oxidative stress improves insu lin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab 2005; 288:E353-E359.
37. Sowers JR. Hypertension, angiotensin II, and oxidative stress. N Engl J Med 2002; 346:1999-2001.
38. Sowers JR, Frohlich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 2004; 88:63-82.
39. Uysal KT, Wiesbrock SM, Hotamisligil GS. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity. Endocrinology 1998; 139:4832-4838.
40. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389:610-614.
41. Taniyama Y, Hitomi H, Shah A, et al. Mechanisms of reactive oxygen speciesdependent downregulation of insulin receptor substrate-1 by angiotensin II. Arterioscler Thromb Vasc Biol 2005; 25:1142-1147 .
42. Lennon R, Pons D, Sabin MA, et al. Saturated fatty acids induce insulin resistance in human podocytes: implications for diabetic nephropathy. Nephrol Dial Transplant 2009; 24:3288-3296.
43. Chavez JA, Knotts TA, Wang LP, et al. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 2003; 278:10297-10303.
44. Decleves AE, Zolkipli Z, Satriano J, et al. Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury. Kidney Int 2014; 85:611-623.
45. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860-867.
46. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96:939-949.
47. Trajcevski KE, O'Neill HM, Wang DC, et al. Enhanced lipid oxidation and maintenance of muscle insulin sensitivity despite glucose intolerance in a diet-induced obesity mouse model. PLoS One 2013; 8:e71747.
48. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
49. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112:1821-1830.
50. Stienstra R, van Diepen JA, T ack CJ, et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci USA 2011; 108:15324-15329.
51. Hivert MF, Sullivan LM, Fox CS, et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 2008; 93:3165-3172.
52. Rajkovic N, Zamaklar M, Lalic K, et al. Relatio nship between obesity, adipocytokines and inflammatory markers in type 2 diabetes: relevance for cardiovascular risk prevention. Int J Environ Res Public Health 2014; 11:4049-4065.
53. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005; 25:2062-2068.
54. Bremer AA, Jialal I. Adipose tissue dysfunction in nascent metabolic syndrome. J Obes 2013; 2013:393192.
55. Huber J, Kiefer FW, Zeyda M, et al. CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J Clin Endocrinol Metab 2008; 93:3215-32 21.
56. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116:1494-15 05.
57. Kamei N, Tobe K, Suzuki R, et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006; 281:26602 -26614.
58. Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006; 116:115-124.
59. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20:1595-1599.
60. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118:1645-1656.
61. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26:439-451.
62. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin I nvest 2006; 116:1784-1792.
63. Yatagai T, Nagasaka S, Taniguchi A, et al. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes m ellitus. Metabolism 2003; 52:1274-1278.
64. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257:79-83.
65. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7:947-953.
66. Yamauchi T, Kamo n J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278:2461-2468.
67. Combs TP, Pajvani UB, Berg AH, et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004; 145:367-383.
68. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8:731-737.
69. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277:25863-25866.
70. Nawrocki AR, Rajala MW, Tomas E, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2006; 281:2654-2660.
71. Ruan H, Miles PD, Ladd CM, et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes 2002; 51 :3176-3188.
72. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8:128 8-1295.
73. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev 2009; 89:1025-1078.
74. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 2004; 29:18-24.
75. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase-development of the energy sensor concept. J Physiol 2006; 574 (Pt 1):7-15.
76. Steinberg GR, Michell BJ, van Denderen BJ, et al. Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 2006; 4:465-474.
77. Yu C,Chen Y,Cline GW,et al., Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle, J Biol Chem 2002, 277, 50230-50236.
78. Shibata T, Takaguri A, Ichihara K, Satoh K. Inhibition of the TNF-alphainduced serine phosphorylation of IRS-1 at 636/639 by AICAR. J Pharmacol Sci 2013; 122:93-102.
79. Lihn AS, Jessen N, Pedersen SB, et al. AICAR stimulates adiponectin and inhibits cytokines in adipose tissue. Biochem Biophys Res Commun 2004; 316:853-858.
80. Sell H, Dietze-Schroeder D, Eckardt K, Eckel J. Cytokine secretion by human adipocytes is differentially regulated by adiponectin, AICAR, and troglitazone. Biochem Biophys Res Commun 2006; 343:700-706.
81. Kumashiro N, Erion DM, Zhang D, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA 2011; 108:16381-16385.
82. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300:1140-1142.
83. Taddeo EP, Laker RC, Breen DS, et al. Opening of the mitochondrial permeability transition pore links mitochondrial dysfunction to insulin resistance in skeletal muscle. Mol Metab 2014; 3:124-134.
84. Turner N, Cooney GJ, Kraegen EW, Bruce CR. Fatty acid metabolism, energy expenditure and insulin resistance in muscle. J Endocrinol 2014; 220:T61-T79.
85. Hansen ME, Tippetts TS, Anderson MC, et al. Insulin increases ceramide synthesis in skeletal muscle. J Diabetes Res 2014; 2014:765784.
86. Wang C, Liu F, Yuan Y, et al. Metformin suppresses lipid accumulation in skeletal muscle by promoting fatty acid oxidation. Clin Lab 2014; 60:887-896.
87. Decleves AE, Mathew AV, Cunard R, Sharma K. AMPK mediates the initiation of kidney disease induced by a high-fat diet. J Am Soc Nephrol 2011; 22:1846 -1855.
88. Deji N, Kume S, Araki S, Soumura M. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am J Physiol Renal Physiol 2009; 296:F118-F126.
89. Kume S, Uzu T, Araki S, et al. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J Am Soc Nephrol 2007; 18:2715-2723.
90. Roubicek T, Bartlova M, Krajickova J, et al. Increased production of proinflammatory cytokines in adipose tissue of patients with end-stage rena l disease. Nutrition 2009; 25:762-768.
91. Siew ED, Ikizler TA. Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease. Semin Dial 2010; 23:378-382.
92. Wilson AC, Schneider MF, Cox C, et al. Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:275 9-2765.
93. Adamczak M, Wiecek A. The adipose tissue as an endocrine organ. Semin Nephrol 2013; 33:2-13.
94. Stemmer K, Perez-Tilve D, Ananthakrishnan G, et al. H igh-fat-diet-induced obesity causes an inflammatory and tumor-promoting microenvironment in the rat kidney. Dis Model Mech 2012; 5:627-635.
95. Mori J, Patel VB, Ramprasath T, et al. Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Renal Physiol 2014; 306:F812-F821.
96. Peairs A, Radjavi A, Davis S, et al. Activation of AMPK inhibits inflammation in MRL/lpr mouse mesangial cells. Clin Exp Immunol 2009; 156:542-551.
97. Furuichi K, Kaneko S, Wada T. Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin Exp Nephrol 2009; 13:9-14.
98. Tarabra E,Giunti S,Barutta F,et al., Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes, Diabetes, 2009, 58, 2109-2118.
99. Wang S, Zhang M, Liang B, et al. AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S protea somes. Circ Res 2010; 106:1117-1128.
100. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013; 493:346-355.
101. Kim D, Lee JE, Jung YJ, et al. Metformin decreases high-fat diet-induced renal injury by regulating the expression of adipokines and the renal AMP-activated protein kinase/acetyl-CoA carboxylase pathway in mice. Int J Mol Med 2013; 32:1293-1302.
102. Deji N, Kume S, Araki S, et al. Role of angiotensin II-mediated AMPK inactivation on obesity-related salt-sensitive hypertension. Biochem Biophys Res Commun 2012; 418:559-564.
103. Ohashi K, Kihara S, Ouchi N, et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006; 47:1108-1116.
104. Sanc hez AP, Zhao J, You Y, et al. Role of the USF1 transcription factor in diabetic kidney disease. Am J Physiol Renal Physiol 2011; 301:F271-F279.
105. Halberg N, Khan T, Trujillo ME, et al. Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol 2009; 29:4467-4483.
106. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69:213-217.
107. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matri x expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97:8015-8020.
108. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331:1286-1292.
109. Sharma K, Jin Y, Guo J, Ziyadeh FN, et al. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertroph y and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996; 45:522-530.
110. Ma LJ, Jha S, Ling H, et al. Divergent effects of low versus high dose anti-T GF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int 2004; 65:106-115.
111. Guan Q, Li S, Gao S, et al. Reduction of chronic rejection of renal allografts by antitransforming growth factor-beta antibody therapy in a rat model. Am J Physiol Renal Physiol 2013; 305:F199-F20 7.
112. Chen S, Iglesias-de la, Cruz MC, Jim B, et al. Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem Biophys Res Commun 2003; 300:16-22.
113. Juarez P, Vilchis-Landeros MM, Ponce-Coria J, et al. Soluble betaglycan reduces renal damage progression in db/db mice. Am J Physiol Renal Physiol 2007; 292:F321-F329.
114. . Kushibiki T, Nagata-Nakajima N, Sugai M, et al. Delivery of plasmid DNA expressing small interference RNA for TGF-beta type II receptor by cationized gelatin to prevent interstitial renal fibrosis. J Control Release 2005; 105:318-331.
115. Meng XM, Chung AC, Lan HY. Role of the TGF-beta/BMP-7/Smad pathways in renal diseases. Clin Sci (Lond) 2013; 124:243-254.
116. Henegar C, Tordj man J, Achard V, et al. Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome Biol 2008; 9:R14.
117. Khan T, Muise ES, Iyengar P, et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol 2009; 29:1575-1591.
118. Yadav H, Quijano C, Kamaraju AK, et al. Protection from obesity and diabetes by blockade of TGF-beta/Smad3 signaling. Cell Metab 2011; 14:67-79.
119. Bartoov-Shifman R, Ridner G, Bahar K, et al. Regulation of the gene encoding GPR40, a fatty acid r eceptor expressed selectively in pancreatic beta cells. J Biol Chem 2007; 282:23561-23571.
120. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999; 42:128-138.
121. Steneberg P, Rubins N, Bartoov-Shifman R, et al. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 2005; 1:245-258.
122. Xiong Y, Miyamoto N, Shibata K, et al. Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc Natl Acad Sci USA 2004; 101 :1045-1050.
123. Hong YH, Nishimura Y, Hishikawa D, et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. Endocrinology 2005; 146:5092-5099.
124. Ge H, Li X, Weiszmann J, et al. Activation ofGprotein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 2008; 149:4519-4526.
125. Pluznick JL, Zou DJ, Zhang X, et al. Functional expression of the olfactory signaling system in the kidney. Proc Natl Acad Sci USA 2009; 106:2059-2064.
126. Pluznick JL. Renal and cardiovascular sensory receptors and blood pressure regulation. Am J Physiol Renal Physiol 2013; 305:F439-F444.